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The number in each cell represents the posterior probability of the row-defining treatment being ranked at the columndefining position. The numbers with biggest probability of ranking first and last are in bold and underscored. EGFR=epidermal growth factor receptor; PbCT=pemetrexed-based chemotherapy; PfCT=pemetrexed-free chemotherapy.
Overall
Exon 19 33  Table S5 . Node-splitting analysis of inconsistency. Significant values (P ≤ 0.05) are in bold and underlined, indicating a significant inconsistency between the direct effect and indirect effects. EGFR=epidermal growth factor receptor; PbCT=pemetrexed-based chemotherapy; PfCT=pemetrexed-free chemotherapy.
Treatment
Rank of possibility (%) (The first sensitivity analysis) 1 2 3 4 5 6 7 8 9 10 Progression-free survival for advanced EGFR-mutated patients Osimertinib  68  27  5  0  0  0  0  0  0  0  Dacomitinib  1  8  30  45  12  4  0  0  0  0  Afatinib  0  0  1  9  51  36  3  0  0  0  Erlotinib  0  0  0  0  5  25  56  12  2  0  Gefitinib  0  0  0  0  0  3  23  65  9  0  Icotinib  1  3  6  12  23  28  13  15  0  0  Erlotinib+Bevacizumab  13  20  29  24  8  5  0  0  0  0  Gefitinib+PbCT  18  42 The number in each cell represents the posterior probability of the row-defining treatment being ranked at the columndefining position. The numbers with biggest probability of ranking first and last are in bold and underscored. EGFR=epidermal growth factor receptor. S2 . Assessment of transitivity. The above characteristics have been evaluated in all trials included in the network. All of the comparisons had similar median age (left) and other main ccharacteristics with P value over 0.05 (right). * Mean age was given instead of median age in the NEJ002 and NEJ009 studies. Information of age in the CTONG0901 and Han et al. studies were presented as younger or older than a specific age that couldn't be integrated in the figure. Figure S4 . A frequency toxicity profile in relation to the incidence (%) of each specific adverse event based on the population of each treatment we included. NA=not applicable; EGFR=epidermal growth factor receptor; TKI=tyrosine kinase inhibitor; ILD= interstitial lung disease; PbCT=pemetrexed-based chemotherapy; PfCT=pemetrexedfree chemotherapy. * Notable incidences of hypertension (58.3%), hemorrhagic events (45.5%) and proteinuria (40.1%) were also associated with erlotinib plus bevacizumab group based on the report of the JO25567 and NEJ026 studies. † When not reported, liver dysfunction was represented by alanine transaminase increased as it was reported in most studies. Figure S5 . Relative toxicity of treatments on seven commonly reported specific adverse events for EGFR-TKIs. A. Pooled odds ratios for each available comparison on each specific adverse event (any grade). Significant values are in bold and colored in gray (less toxicity) and light yellow (more toxicity). B. Ranking curves indicating the probability of each comparable treatment being ranked first on each specific adverse event. If a study reported zero adverse events in any arm, the classic half integer continuity correction (adding a 0.5 to each cell) was applied for data preparation. NA=not applicable; EGFR=epidermal growth factor receptor; TKI=tyrosine kinase inhibitor; PbCT=pemetrexed-based chemotherapy; PfCT=pemetrexed-free chemotherapy; ILD=interstitial lung disease. † When not reported, liver dysfunction was represented by alanine transaminase increased as it was reported in most studies. Results of all comparisons in overall epidermal growth factor receptor mutated (blue) population, and exon 19 deletion (orange) and Leu858Arg (green) subpopulations were consistent between pairwise and network meta-analyses. CrI=credible interval; PbCT=pemetrexed-based chemotherapy; PfCT=pemetrexed-free chemotherapy.
Figure S1. Convergence of the three chains established by inspection of the history feature and the Brooks-Gelman-Rubin diagnostic for progression-free survival (A and B), overall survival (C and D), objective response rate (E and F), and grade ≥3 adverse events (G and H).
Characteristic Intervention arm Control arm
29 Figure S8 . Network diagrams for the first sensitivity analysis including only phase III trials. A. Comparisons on progression-free survival (blue line) and overall survival (orange line) in advanced EGFR-mutated patients. B. Comparisons on objective response rate (green line) and grade ≥3 adverse events (purple line) in advanced EGFR-mutated patients. C. Comparisons on progression-free survival (blue line) and overall survival (orange line) in exon 19 deletion and Leu858Arg subpopulations. Each circular node represents a type of treatment. The node size is proportional to the total number of patients receiving a treatment (in square brackets). Each line represents a type of head-to-head comparison. The width of lines is proportional to the number of trials comparing the connected treatments. EGFR=epidermal growth factor receptor; PbCT=pemetrexed-based chemotherapy; PfCT=pemetrexed-free chemotherapy. Figure S11. Network diagrams for the second sensitivity analysis excluding the FLAURA study. A. Comparisons on progression-free survival (blue line) and overall survival (orange line) in advanced EGFR-mutated patients. B. Comparisons on objective response rate (green line) and grade ≥3 adverse events (purple line) in advanced EGFR-mutated patients. C. Comparisons on progression-free survival (blue line) and overall survival (orange line) in exon 19 deletion and Leu858Arg subpopulations. Each circular node represents a type of treatment. The node size is proportional to the total number of patients receiving a treatment (in square brackets). Each line represents a type of head-to-head comparison. The width of lines is proportional to the number of trials comparing the connected treatments. PbCT=pemetrexedbased chemotherapy; PfCT=pemetrexed-free chemotherapy; EGFR=epidermal growth factor receptor.
Figure S12: Pooled estimates of the second sensitivity analysis excluding the FLAURA study. A. Pooled hazard ratios (95% credible intervals) for progression-free survival (upper triangle) and overall survival (lower triangle). B. Pooled odds ratios (95% credible intervals) for grade ≥3 adverse events (upper triangle) and objective response rate (lower triangle). Result in each cell is presented as hazard ratio or odds ratio (95% credible interval) for the comparison of row-defining treatment versus column-defining treatment. Hazard ratio <1 and odds ratio >1 favor row-defining treatment. Significant results are in bold and underlined. C. Ranking curves indicating the probability of each comparable treatment being ranked first on progression-free survival (black line), overall survival (pink line), objective response rate (green line) and grade ≥3 adverse events (red line). Dac=dacomitinib; Afa=afatinib; Erl=erlotinib; Gef=gefitinib; Ico=icotinib; Cet=cetuximab; Bev=bevacizumab; Gef+P= Gefitinib plus pemetrexed; PbCT=pemetrexed-based chemotherapy; PfCT=pemetrexed-free chemotherapy. Figure S14 . Network diagrams for the third sensitivity analysis stratifying patients by Asian and non-Asian. A. Comparisons on progression-free survival (blue line) and overall survival (orange line) in Asian patients. B. Comparisons on objective response rate (green line) and grade ≥3 adverse events (purple line) in Asian patients. C. Comparisons on progression-free survival in non-Asian patients. Each circular node represents a type of treatment. The node size is proportional to the total number of patients receiving a treatment (in square brackets). Each line represents a type of head-to-head comparison. The width of lines is proportional to the number of trials comparing the connected treatments. PbCT=pemetrexed-based chemotherapy; PfCT=pemetrexed-free chemotherapy. 
